Multicenter comparison of first- and second-generation IMx tacrolimus microparticle enzyme immunoassays in liver and kidney transplantation

Therapeutic Drug Monitoring

Volumn 20, Issue 6, 1998, Pages 676-679

  Brunet, Mercè ^a,d   Pou, Leonor ^b   Manzanares, Cecelia ^c   Palacios, Gonzalo ^c   Corbella, Jacint ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c ABBOTT LABORATORIES   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Levels; Sensitivity; Tacrolimus; Therapeutic monitoring

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MICROPARTICLE ENZYME IMMUNOASSAY; PRIORITY JOURNAL; REPRODUCIBILITY;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; SENSITIVITY AND SPECIFICITY; TACROLIMUS;

EID: 0031726829     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199812000-00017     Document Type: Article

References (13)

1. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression in liver transplantation. The U.S. Multicenter FK06 Liver Study Group. N Engl J Med 1994;331:1110-5.
2. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicenter Liver Study Group. Lancet 1994;344:423-8.
3. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 1995;59:485-90.
4. Peters DH, Fitton A, Greg L, et al. Tacrolimus. A review of its Pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-794.
5. McMaster P, Mirza DF, Ismail T, et al. Therapeutic drug monitoring of tacrolimus in clinical transplantation. Ther Drug Monit 1995;17:602-5.
6. Pou L, Brunet M, Andres I, et al. Influence of post-transplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 1998;11:270-1.
7. Laskow DA, Vincenti F, Neeylan JF, et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation. Transplantation 1996;62:900-5.
8. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
9. Grenier FC, Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for the IMx analyzer. Transplant Proc 1991;23:2748-9.
10. Bland JM, and Altman DJ. Statistical methods for assessing agreement between two methods. Lancet 1986;1:307-10.
11. Wallemacq PE, Firdaous I, Hassoun A. Improvement and assessment of enzyme-linked immunosorbent assay to detect low FK506 concentrations in plasma or whole blood within 6 h. Clin Chem 1993;39:1045-9.
12. Wallemacq PE, Leal T, Besse T, et al. Imx Tacrolimus II vs Tacrolimus Microparticle Enzyme Immunoassay evaluated in renal and hepatic transplant patients. Clin Chem 1997;43:1989-91.
13. Brunet M, Pou L, Torra M, et al. Comparative analysis of tacrolimus in whole blood liver transplant recipients by PRO-TRAC Enzyme-Linked Immunosorbent Assay and Microparticle Enzyme Immunoassay IMx methods. Ther Drug Monit 1996;18:706-9.